InSite Vision sees DOUBle as it begins 900-patient PhIII study in blepharitis
This article was originally published in Scrip
Executive Summary
InSite Vision has begun patient enrollment in a US for a 900-patient, Phase III trial dubbed “DOUBle” where the firm is actually testing two investigational drug candidates in the same study for the same indication: blepharitis, or lid margin disease. There is no FDA-approved treatment for this chronic condition involving inflammation of the eyelid.